News | September 08, 2010

Ticagrelor Demonstrates Advantages Over Clopidogrel

September 8, 2010 – The increased effectiveness of ticagrelor (Brilinta) in overcoming high platelet reactivity as compared to the gold-standard of clopidogrel (Plavix) was shown in data presented last week at the European Society of Cardiology (ESC) Congress in Stockholm.

Pooled pharmacologic data from the ONSET/OFFSET and RESPOND trials compared high platelet reactivity between clopidogrel and ticagrelor use. This reactivity has been linked to complications following percutaneous coronary intervention (PCI).

Ticagrelor showed better platelet inhibition and faster offset than clopidogrel in the ONSET/OFFSET study. The RESPOND study also confirmed better platelet inhibition with ticagrelor in both clopidogrel responders and nonresponders. The effects of ticagrelor were observed within two hours, while clopidogrel took between four and eight hours.

One of the chief advantages of ticagrelor is its ability to reverse its effects quickly as compared to clopidogrel, which was also demonstrated in these data.

In July, the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee voted to recommend that the FDA approve ticagrelor for the reduction of thrombotic events in patients with acute coronary syndromes (ACS). The panel reviewed data from the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study, an outcomes trial of more than 18,000 patients whose data showed ticagrelor was superior to clopidogrel in the long-term reduction of cardiovascular events.

The FDA is expected to make an approval decision this month.

Related Content

PinnacleHealth First in Pennsylvania to Implant Sentinel Cerebral Protection System
News | Embolic Protection Devices| August 23, 2017
PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Overlay Init